NASDAQ:BLRX

BioLineRx Competitors

$2.76
-0.10 (-3.50 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.76
Now: $2.76
$2.86
50-Day Range
$2.73
MA: $2.97
$3.50
52-Week Range
$1.40
Now: $2.76
$4.23
Volume350,044 shs
Average Volume1.82 million shs
Market Capitalization$117.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08

Competitors

BioLineRx (NASDAQ:BLRX) Vs. FLXN, ETNB, FBRX, FBIO, AKBA, and VSTM

Should you be buying BLRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BioLineRx, including Flexion Therapeutics (FLXN), 89bio (ETNB), Forte Biosciences (FBRX), Fortress Biotech (FBIO), Akebia Therapeutics (AKBA), and Verastem (VSTM).

Flexion Therapeutics (NASDAQ:FLXN) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Flexion Therapeutics and BioLineRx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flexion Therapeutics01913.00
BioLineRx00203.00

Flexion Therapeutics currently has a consensus target price of $20.4545, suggesting a potential upside of 117.60%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than Flexion Therapeutics.

Earnings & Valuation

This table compares Flexion Therapeutics and BioLineRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flexion Therapeutics$72.96 million6.43$-149,770,000.00($3.93)-2.39
BioLineRxN/AN/A$-25,450,000.00($2.55)-1.08

BioLineRx has lower revenue, but higher earnings than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Flexion Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Profitability

This table compares Flexion Therapeutics and BioLineRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flexion Therapeutics-153.90%N/A-53.31%
BioLineRxN/A-96.27%-55.87%

Insider and Institutional Ownership

17.5% of BioLineRx shares are held by institutional investors. 17.0% of Flexion Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioLineRx beats Flexion Therapeutics on 7 of the 13 factors compared between the two stocks.

89bio (NASDAQ:ETNB) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and BioLineRx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
89bio00613.14
BioLineRx00203.00

89bio currently has a consensus target price of $62.4286, suggesting a potential upside of 165.54%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than 89bio.

Earnings & Valuation

This table compares 89bio and BioLineRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A$-57,420,000.00($24.49)-0.96
BioLineRxN/AN/A$-25,450,000.00($2.55)-1.08

BioLineRx is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 89bio and BioLineRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
89bioN/A-49.56%-46.52%
BioLineRxN/A-96.27%-55.87%

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

89bio beats BioLineRx on 7 of the 11 factors compared between the two stocks.

Forte Biosciences (NASDAQ:FBRX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Forte Biosciences and BioLineRx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forte Biosciences00703.00
BioLineRx00203.00

Forte Biosciences currently has a consensus target price of $82.00, suggesting a potential upside of 136.65%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than Forte Biosciences.

Earnings & Valuation

This table compares Forte Biosciences and BioLineRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte Biosciences$40,000.0011,702.17$-63,520,000.00($40.33)-0.86
BioLineRxN/AN/A$-25,450,000.00($2.55)-1.08

BioLineRx has lower revenue, but higher earnings than Forte Biosciences. BioLineRx is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Forte Biosciences has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Profitability

This table compares Forte Biosciences and BioLineRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forte BiosciencesN/A-417.87%-248.28%
BioLineRxN/A-96.27%-55.87%

Insider and Institutional Ownership

53.0% of Forte Biosciences shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 10.9% of Forte Biosciences shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioLineRx beats Forte Biosciences on 7 of the 11 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Insider and Institutional Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Fortress Biotech and BioLineRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-131.98%-44.08%-19.06%
BioLineRxN/A-96.27%-55.87%

Risk & Volatility

Fortress Biotech has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Earnings & Valuation

This table compares Fortress Biotech and BioLineRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million12.77$-39,960,000.00($0.73)-6.75
BioLineRxN/AN/A$-25,450,000.00($2.55)-1.08

BioLineRx has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Fortress Biotech and BioLineRx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00603.00
BioLineRx00203.00

Fortress Biotech currently has a consensus target price of $10.75, suggesting a potential upside of 118.05%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than Fortress Biotech.

Summary

Fortress Biotech beats BioLineRx on 8 of the 12 factors compared between the two stocks.

Akebia Therapeutics (NASDAQ:AKBA) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Insider and Institutional Ownership

69.0% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 2.6% of Akebia Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Akebia Therapeutics and BioLineRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akebia Therapeutics-126.86%-68.51%-34.01%
BioLineRxN/A-96.27%-55.87%

Volatility and Risk

Akebia Therapeutics has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Earnings and Valuation

This table compares Akebia Therapeutics and BioLineRx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$335 million1.39$-279,660,000.00($1.63)-1.86
BioLineRxN/AN/A$-25,450,000.00($2.55)-1.08

BioLineRx has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akebia Therapeutics and BioLineRx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akebia Therapeutics12502.50
BioLineRx00203.00

Akebia Therapeutics currently has a consensus price target of $9.6250, suggesting a potential upside of 217.66%. BioLineRx has a consensus price target of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's stronger consensus rating and higher probable upside, analysts clearly believe BioLineRx is more favorable than Akebia Therapeutics.

Summary

Akebia Therapeutics beats BioLineRx on 9 of the 13 factors compared between the two stocks.

Verastem (NASDAQ:VSTM) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Insider and Institutional Ownership

42.2% of Verastem shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 2.9% of Verastem shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Verastem and BioLineRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verastem-590.19%-189.37%-67.69%
BioLineRxN/A-96.27%-55.87%

Volatility and Risk

Verastem has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Earnings and Valuation

This table compares Verastem and BioLineRx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verastem$17.46 million26.55$-149,210,000.00($2.00)-1.35
BioLineRxN/AN/A$-25,450,000.00($2.55)-1.08

BioLineRx has lower revenue, but higher earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Verastem and BioLineRx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verastem00203.00
BioLineRx00203.00

Verastem currently has a consensus price target of $3.00, suggesting a potential upside of 11.11%. BioLineRx has a consensus price target of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher probable upside, analysts clearly believe BioLineRx is more favorable than Verastem.

Summary

BioLineRx beats Verastem on 7 of the 11 factors compared between the two stocks.


BioLineRx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.40-11.6%$469.29 million$72.96 million-3.04High Trading Volume
News Coverage
Gap Down
89bio logo
ETNB
89bio
1.6$23.51-1.2%$468.93 millionN/A-4.66
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$34.65-2.1%$468.09 million$40,000.00-1.50
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.93-11.2%$467.89 million$36.63 million-5.80High Trading Volume
News Coverage
Gap Up
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.03-1.7%$465.11 million$335 million-1.02
Verastem logo
VSTM
Verastem
1.3$2.70-4.8%$463.50 million$17.46 million-1.91Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.97-0.7%$455.80 million$109.33 million-2.18Analyst Report
Geron logo
GERN
Geron
1.4$1.43-0.7%$455.50 million$460,000.00-4.09Decrease in Short Interest
News Coverage
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.38-2.1%$454.75 million$102.31 million6.54Increase in Short Interest
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.21-0.6%$449.54 millionN/A0.00
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.09-1.8%$447.93 millionN/A0.00
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.38-1.9%$446.09 million$56.50 million0.00
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$6.83-1.3%$442.48 million$57.49 million-5.74Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.87-0.6%$441.13 million$22.27 million-3.86Insider Buying
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.16-4.1%$440.71 million$6.07 million-3.43
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.90-2.6%$438.26 million$6.68 million-4.70
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.90-0.7%$437.39 millionN/A-12.04
BCEL
Atreca
1.7$11.63-1.3%$428.35 millionN/A-4.12News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.45-0.9%$427.85 millionN/A-3.46
XOMA logo
XOMA
XOMA
1.3$37.53-1.2%$422.33 million$18.37 million-33.81Increase in Short Interest
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$33.03-1.9%$408.42 million$206.55 million-16.60
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.55-4.5%$399.47 million$28.91 million-5.92Gap Down
DURECT logo
DRRX
DURECT
1.4$1.75-0.6%$397.60 million$29.56 million-34.99
Sesen Bio logo
SESN
Sesen Bio
1.2$2.33-0.4%$394.67 millionN/A-5.30Decrease in Short Interest
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$16.80-4.0%$391.47 millionN/A0.00
BeyondSpring logo
BYSI
BeyondSpring
1.2$9.96-2.8%$389.85 millionN/A-4.88
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.31-1.1%$389.68 million$16.54 million-3.38
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.32-0.6%$389.56 million$1.98 million-3.81
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
1.0$19.55-0.5%$387.01 million$362.21 million23.55
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$4.93-6.7%$385.94 million$380,000.000.00
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$13.01-0.4%$383.85 million$18.15 million-3.06Increase in Short Interest
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.6$9.48-1.5%$381.65 million$272.30 million-6.63
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$11.51-0.0%$376.06 millionN/A-4.00Analyst Report
Athersys logo
ATHX
Athersys
1.3$1.73-0.6%$372.37 million$5.63 million-4.68
Athenex logo
ATNX
Athenex
1.6$3.98-1.0%$371.95 million$101.23 million-2.73Increase in Short Interest
UroGen Pharma logo
URGN
UroGen Pharma
1.8$17.48-0.5%$365.28 million$20,000.00-2.73
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.45-7.6%$362.86 million$9.48 million-0.25
Homology Medicines logo
FIXX
Homology Medicines
1.6$7.18-0.1%$362.50 million$1.67 million-2.63High Trading Volume
News Coverage
Theratechnologies logo
THTX
Theratechnologies
1.1$3.83-3.4%$358.94 million$63.22 million-12.34
Oncorus logo
ONCR
Oncorus
1.7$13.97-3.7%$357.98 millionN/A0.00Increase in Short Interest
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.40-2.0%$355.32 million$3.89 million-3.87
Cue Biopharma logo
CUE
Cue Biopharma
1.3$11.63-1.1%$354.22 million$3.46 million-7.41High Trading Volume
Gap Down
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$1.09-0.0%$353.07 millionN/A-0.31Increase in Short Interest
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.45-1.4%$347.97 million$111.39 million24.64
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$10.17-6.7%$347.59 million$28.95 million-14.53Increase in Short Interest
BELLUS Health logo
BLU
BELLUS Health
1.7$4.38-3.7%$343.12 million$30,000.00-7.42
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.4$13.41-0.4%$341.16 millionN/A-10.16
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$7.16-2.2%$332.19 million$6.29 million-4.11
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.0$9.53-2.8%$330.32 millionN/A0.00Gap Down
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$12.47-0.6%$323.85 million$11.94 million-7.60
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.